Vaxxas Home

Vaxxas Nanopatch™ Technology

Vaccine Application System
Nanopatch Microprojections
Skip Navigation LinksPages > News > Vaccine Industry Excellence Awards

Vaxxas

News

Vaccine Industry Excellence Awards

April 17, 2012
WASHINGTON, DC, USA and BRISBANE, QUEENSLAND, AUSTRALIA

The $15m syndicated investment in Vaxxas Pty Ltd, developers of the Nanopatch™, a new needle-free vaccine delivery system, was judged the Best Venture Capital Investment at the 2012 Vaccine Industry Excellence Awards, held at the World Vaccine Congress in Washington.

The Vaccine Industry Excellence Awards have been created to honour and recognise the efforts, accomplishments, and positive contributions of companies and individuals in the vaccine industry over the previous 12 months. This year's awards were voted upon by global industry representatives and attended by more than 500 senior vaccine industry professionals.

The judging criteria for the award included the structure of the deal, how innovative the investment model was, and what impact the investing company has had and will have on the business.